Welcome to our dedicated page for Merrimack Pharma news (Ticker: MACK), a resource for investors and traders seeking the latest updates and insights on Merrimack Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merrimack Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merrimack Pharma's position in the market.
Merrimack Pharmaceuticals, Inc. (MACK) reported its third quarter 2020 financial results, with a net loss of $1.0 million, or $0.08 per share, compared to a loss of $0.7 million in Q3 2019. General and administrative expenses significantly decreased to $1.0 million from $4.3 million in the prior year. Cash reserves as of September 30, 2020, were $15.8 million, down from $16.6 million at year-end 2019. The company is focused on cash conservation and expects potential milestone payments from Ipsen and Elevation Oncology, who continue patient enrollment in ongoing clinical trials.